lasofoxifene sold brand name fablyn nonsteroidal selective estrogen receptor modulator serm marketed pfizer lithuania portugal prevention treatment osteoporosis treatment vaginal result exclusive research collaboration ligand pharmaceuticals lgnd also appears statistically significant effect reducing breast cancer women according study published journal national cancer institute postmenopausal women osteoporosis lasofoxifene dose mg per day associated reduced risks nonvertebral vertebral fractures erpositive breast cancer coronary heart disease stroke increased risk venous thromboembolic studies breast cancer prevention lasofoxifene showed reduction breast cancer incidence reduction specific incidence estrogen receptorpositive breast cancers significantly higher reductions found related serms tamoxifen accordance network metaanalysis serms breast cancer prevention found highest reduction risk lasofoxifene reduction even greater observed aromatase inhibitors generally found confer greater risk reduction also shown promise mutant patients approximately patients harboring lasofoxifene selectively binds erα erβ high erα nm similar estradiol nm least higher tamoxifen lasofoxifene greatly improved oral bioavailability relative tamoxifen raloxifene may also involved greater lasofoxifene naphthalene desmethyl dihydro analogue september pfizer received nonapprovable letter us food drug administration regarding lasofoxifene trade name oporia selective estrogen receptor modulator prevention osteoporosis january ligand pharmaceuticals marketing partner pfizer submitted new drug application lasofoxifene expected marketed tradename fablyn lasofoxifene approved eu brand name fablyn emea march lasofoxifene development sermonix pharmaceuticals treatment metastatic breast cancer dyspareunia associated vaginal atrophy united states also researched potential treatment ovarian december lasofoxifene phase iii clinical trials breast cancer phase ii clinical studies httpsenwikipediaorgwikilasofoxifene